Zenas Biopharma, Inc. (ZBIO)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$26.87-4.82%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Zenas Biopharma, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	11.26M
EPS	—	-1.112
Annual ending 2026-12-31
Revenue	—	10.38M
EPS	—	-5.634
Annual ending 2027-12-31
Revenue	—	57.92M
EPS	—	-5.059

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash funds operations through Q2 2029	The company has enough cash to operate through Q2 2029.	Intact	Cash runs out before Q2 2029	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Positive phase 3 trial results for obexelimab	Positive trial results support future approval chances.	Intact	Negative or inconclusive trial results	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Submit Biologics License Application (BLA) to FDA in Q2 2026	Zenas BioPharma plans to submit a key drug application in Q2 2026.	Intact	BLA submission delayed beyond Q2 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

$0.06B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$63,257,904	4 / 5
2026-07-25	Unavailable	$63,257,904	4 / 5
2026-07-26	Unavailable	$63,257,904	4 / 5
2026-07-27	Unavailable	$63,257,904	4 / 5
2026-07-28	Unavailable	$63,757,904	4 / 5
2026-07-29	Unavailable	$63,757,904	4 / 5
2026-07-30	Unavailable	$63,749,500	2 / 6
2026-07-31	Unavailable	$63,757,904	4 / 5
2026-08-01	Unavailable	$63,757,904	4 / 5
2026-08-02	Unavailable	$63,757,904	4 / 5
2026-08-03	Unavailable	$63,749,500	2 / 6
2026-08-04	Unavailable	$63,749,500	2 / 6
2026-08-05	Unavailable	$63,757,904	4 / 5
2026-08-06	Unavailable	$63,757,904	4 / 5
2026-08-08	Unavailable	$63,749,500	2 / 6
2026-08-09	Unavailable	$63,757,904	4 / 5
2026-08-10	Unavailable	$63,749,500	2 / 6
2026-08-12	Unavailable	$63,757,904	4 / 5
2026-08-13	Unavailable	$63,749,500	2 / 6
2026-08-14	Unavailable	$63,757,904	4 / 5
2026-08-15	Unavailable	$63,757,904	4 / 5
2026-08-16	Unavailable	$63,757,904	4 / 5
2026-08-17	Unavailable	$63,757,904	4 / 5
2026-08-18	Unavailable	$63,757,904	4 / 5
2026-08-19	Unavailable	$63,757,904	4 / 5
2026-08-20	Unavailable	$53,968,466	4 / 5
2026-08-21	Unavailable	$53,968,466	4 / 5
2026-08-22	Unavailable	$53,968,466	4 / 5
2026-08-23	Unavailable	$53,968,466	4 / 5
2026-08-24	Unavailable	$53,968,466	4 / 5
2026-08-25	Unavailable	$53,968,466	4 / 5
2026-08-26	Unavailable	$53,968,466	4 / 5
2026-08-27	Unavailable	$53,968,466	4 / 5
2026-08-28	Unavailable	$53,968,466	4 / 5
2026-08-29	Unavailable	$53,968,466	4 / 5
2026-08-30	Unavailable	$53,968,466	4 / 5
2026-08-31	Unavailable	$53,968,466	4 / 5
2026-09-01	Unavailable	$53,968,466	4 / 5
2026-09-02	Unavailable	$53,968,466	4 / 5
2026-09-03	Unavailable	$53,968,466	4 / 5
2026-09-04	Unavailable	$53,968,466	4 / 5
2026-09-05	Unavailable	$53,968,466	4 / 5
2026-09-06	Unavailable	$53,968,466	4 / 5
2026-09-07	Unavailable	$53,968,466	4 / 5
2026-09-08	Unavailable	$53,968,466	4 / 5
2026-09-09	Unavailable	$53,968,466	4 / 5
2026-09-10	Unavailable	$53,968,466	4 / 5
2026-09-11	Unavailable	$53,968,466	4 / 5
2026-09-12	Unavailable	$53,968,466	4 / 5
2026-09-13	Unavailable	$53,968,466	4 / 5
2026-09-14	Unavailable	$53,968,466	4 / 5
2026-09-15	Unavailable	$53,968,466	4 / 5
2026-09-16	Unavailable	$53,968,466	4 / 5
2026-09-17	Unavailable	$53,968,466	4 / 5
2026-09-18	Unavailable	$53,968,466	4 / 5
2026-09-19	Unavailable	$53,968,466	4 / 5
2026-09-20	Unavailable	$53,968,466	4 / 5
2026-09-21	Unavailable	$53,968,466	4 / 5
2026-09-22	Unavailable	$53,968,466	4 / 5
2026-09-23	Unavailable	$53,968,466	4 / 5
2026-09-24	Unavailable	$53,968,466	4 / 5
2026-09-25	Unavailable	$53,968,466	4 / 5
2026-09-26	Unavailable	$53,968,466	4 / 5
2026-09-27	Unavailable	$53,968,466	4 / 5
2026-09-28	Unavailable	$53,968,466	4 / 5
2026-09-29	Unavailable	$53,968,466	4 / 5
2026-09-30	Unavailable	$53,968,466	4 / 5
2026-10-01	Unavailable	$53,968,466	4 / 5
2026-10-02	Unavailable	$57,924,424	4 / 5
2026-10-03	Unavailable	$57,924,424	4 / 5
2026-10-04	Unavailable	$57,924,424	4 / 5
2026-10-05	Unavailable	$57,924,424	4 / 5
2026-10-06	Unavailable	$57,924,424	4 / 5
2026-10-07	Unavailable	$57,924,424	4 / 5
2026-10-08	Unavailable	$57,924,424	4 / 5
2026-10-09	Unavailable	$57,924,424	4 / 5
2026-10-10	Unavailable	$57,924,424	4 / 5
2026-10-11	Unavailable	$57,924,424	4 / 5
2026-10-12	Unavailable	$57,924,424	4 / 5
2026-10-13	Unavailable	$57,924,424	4 / 5
2026-10-14	Unavailable	$57,924,424	4 / 5
2026-10-15	Unavailable	$57,924,424	4 / 5
2026-10-16	Unavailable	$57,924,424	4 / 5
2026-10-17	Unavailable	$57,924,424	4 / 5
2026-10-18	Unavailable	$57,924,424	4 / 5
2026-10-19	Unavailable	$57,924,424	4 / 5
2026-10-20	Unavailable	$57,924,424	4 / 5
2026-10-21	Unavailable	$57,924,424	4 / 5
2026-10-22	Unavailable	$57,924,424	4 / 5
2026-10-23	Unavailable	Unavailable	4 / 4
2026-10-24	Unavailable	Unavailable	4 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	1
2026-06-01	7	1
2026-07-01	7	1
2026-08-01	7	1
2026-09-01	7	1
2026-10-01	7	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

GuggenheimSep 30

$55.00New observation · no comparable prior

$0$30.25$60.50

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash funds operations through Q2 2029Direct metric needs a verified mapping
Positive phase 3 trial results for obexelimabDirect metric needs a verified mapping
Submit Biologics License Application (BLA) to FDA in Q2 2026Direct metric needs a verified mapping

Next proof point

Next earnings date unavailable

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.6%Typical daily move · historical

Downside history

-64.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Zenas Biopharma, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth investment in a loss-making biotech, with the thesis centered on obexelimab’s regulatory path. The long-term thesis is at a watch stage: management has advanced key milestones, but recent performance remains below its industry cohort.

What's priced into Zenas Biopharma, Inc.

ZBIO trades at a 16.57% premium to peers, with low confidence in the valuation model and optionality as the main reason for the gap. The evidence points to some premium for future possibilities, but does not show that the market assumes a specific commercial outcome.

What the fundamentals likely do

Near term, results may remain uneven: ZBIO reported an earnings miss in August after a beat in May, and the next print carries a 52% miss probability in the snapshot. Over the multi-year view, regulatory progress is tangible: the FDA accepted the obexelimab application with a May 27, 2027 action date, while an EMA submission is expected in the second half of 2026; cash and investments were $673.9 million in Q2 2026, and management expects funding through Q2 2029.

What Zenas Biopharma, Inc. hinges on

The thesis hinges on the obexelimab regulatory process staying on schedule and management maintaining its stated funding runway. A guidance cut or further weakness in jobs data would add pressure, while strong results and guidance from sector leaders could support healthcare-sector momentum.